(VIANEWS) – The NASDAQ ended the session with Castle Biosciences rising 9.07% to $15.52 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.48% to $12,851.24, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Castle Biosciences’s last close was $14.23, 51.91% below its 52-week high of $29.59.
About Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-3.36.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.2%.
Yearly Top and Bottom Value
Castle Biosciences’s stock is valued at $15.52 at 18:06 EST, way under its 52-week high of $29.59 and way higher than its 52-week low of $9.26.
Revenue Growth
Year-on-year quarterly revenue growth grew by 43.9%, now sitting on 167.52M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 1.3% and a drop 12.8% for the next.
Volume
Today’s last reported volume for Castle Biosciences is 261458 which is 4.89% above its average volume of 249248.
More news about Castle Biosciences (CSTL).
